CYP19A1 and cancer: Endocrine therapy mainly includes selective estrogen receptor modulators (SERM), and aromatase inhibitors (AI), which can impede estrogen stimulation of cancer cells through competitive binding to ER or through inhibition of estrogen synthesis (67).